Exatecan derivative, ligand drug conjugate, antibody conjugate, and use
By connecting exitecan with hydroxyacetic acid to form amide derivatives to form antibody-conjugated drugs, the problem of exitecan's narrow treatment window in chemotherapy alone is solved, and the inhibition efficiency of tumor cells is significantly improved. It is suitable for clinical applications. , especially in types such as lung cancer related to HER3 expression, showed excellent efficacy.
Patent Information
- Application Number
- PCT/CN2024/096558
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-31
- Filing Date
- 2024-05-31
- Publication Date
- 2024-12-05
AI Technical Summary
The existing exitecan as a chemotherapy drug alone has not been successfully marketed. It is speculated that its higher cellular activity leads to a narrow therapeutic window and is insufficient in the application of ADC drugs. It is necessary to explore better anti-tumor active compounds to Improve its performance in treatment.
A new class of compounds and antibody drug conjugates were developed to form an antibody-conjugated drug Enhertu, which binds specific antibodies or antigen-binding fragments thereof to target HER3-expressed tumor cells.
It significantly improves the inhibitory efficiency of tumor cells, is suitable for clinical drug applications, and provides stronger tumor suppression effects, especially in types such as lung cancer related to HER3 expression.
Smart Images

Figure PCTCN2024096558-FTAPPB-I100001 
Figure PCTCN2024096558-FTAPPB-I100002 
Figure PCTCN2024096558-FTAPPB-I100003
Abstract
Description
Exitecan derivatives, ligand-drug conjugates, antibody conjugates and uses thereof Technical Field
[0001] The present invention relates to the field of medical technology, and in particular to a class of novel structural exotecan analogs, ligand-drug conjugates, antibody-drug conjugates and uses thereof. Background Art
[0002] Antibody-drug conjugates (ADCs), as a new type of targeted drug, are generally composed of three parts: antibodies or antibody-like ligands, small molecule drugs, and linkers that couple the ligands and drugs. Antibody-drug conjugates use the antibody's specific recognition of antigens to transport drug molecules to the vicinity of target cells and effectively release drug molecules to achieve therapeutic purposes. In 2000, Mylotarg, an ADC drug from Pfizer, was first launched on the market, and ADC, a field full of potential and challenges, has since entered the public eye. In recent years, the pharmaceutical market has ushered in a new round of ADC research and development boom. Currently, a total of 13 ADC drugs have been launched worldwide. In June 2021, Rongchang Bio's vedicizumab was approved for marketing. This is the third ADC antibody approved in China and the first domestically produced ADC.
[0003] Ixitectcan, a small molecule anti-tumor compound, is a camptothecin derivative known to exhibit anti-tumor effects by inhibiting DNA topoisomerase I. Developed by Daiichi Sankyo, it was initially advanced to Phase III clinical trials as a standalone chemotherapy agent, with primary indications for bone cancer, prostate cancer, breast cancer, and pancreatic cancer. Unlike irinotecan, currently in clinical use, Ixitectcan does not require enzyme activation. Furthermore, compared to SN-38, the active ingredient in irinotecan, and topotecan, also in clinical use, Ixitectcan exhibits stronger topoisomerase I inhibitory activity and exhibits enhanced cytotoxicity against various cancer cells in vitro. Ixitectcan has not yet been successfully marketed as a standalone chemotherapy agent, presumably due to its high cellular activity, resulting in a narrow therapeutic window.
[0004] DS-8201a (trade name: Enhertu), an antibody-drug conjugate jointly developed and commercialized by Daiichi Sankyo and AstraZeneca, was launched in December 2019. This drug forms an amide derivative of exotecan and glycolic acid and connects them to form an ADC. As a new generation of antibody-drug conjugate, Enhertu has shown the potential to become a blockbuster.
[0005] It is extremely necessary and urgent to explore and discover exotecan derivatives with better anti-tumor activity, improve the safety and efficacy of small molecule anti-tumor compounds in ADC drug applications, and thus obtain anti-tumor drugs with excellent therapeutic effects.
[0006] Summary of the Invention
[0007] The first aspect of the present invention provides a compound having a structure shown in Formula A or a pharmaceutically acceptable salt thereof,
[0008] Wherein, R1 is -C(O)-(CH2) m2 R2;
[0009] R2 is a 6-10 membered aryl group, a 5-10 membered heteroaryl group containing 1, 2 or 3 heteroatoms independently selected from N, O and S, a 3-8 membered cycloalkyl group or a 3-8 membered heterocycloalkyl group containing 1, 2 or 3 heteroatoms independently selected from N, O and S, and the aryl, heteroaryl, cycloalkyl and heterocycloalkyl groups are each independently substituted by 2, 3 or more R3. Preferably, the aryl, heteroaryl, cycloalkyl and heterocycloalkyl groups are each independently substituted by 2, 3, 4 or 5 R3;
[0010] R3 is independently selected from halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, amino, nitro, hydroxy, cyano, C 1-6 Alkoxy, -NH-C 1-6 Alkyl, and -N(C 1-6 alkyl)2, and at least one R3 is an amino group, and when R2 has two R3, the R3 that is an amino group and the -C(O)-(CH2) in R1 m2 - the respective attachment sites in R2 are not in a para-positional relationship; and
[0011] m2 is selected from 1, 2, 3, 4, 5 and 6.
[0012] In one embodiment,
[0013] R1 is -CO-CH2-R2; in one embodiment,
[0014] R2 is a 6-10 membered aryl or a 5-10 membered heteroaryl containing 1, 2 or 3 heteroatoms independently selected from N, O and S, and the aryl and heteroaryl are each independently substituted by 2, 3, 4 or 5 R3; preferably, R2 is a 6-10 membered aryl substituted by 2, 3, 4 or 5 R3; preferably, R2 is a phenyl substituted by 2, 3 or 4 R3; in one embodiment,
[0015] Each occurrence of R3 is independently selected from F, Cl, Br, I, C 1-3 Alkyl, C 1-3 Haloalkyl, amino, nitro, hydroxy, cyano, C 1-3 Alkoxy, -NH-C 1-3 Alkyl, and -N(C 1-3alkyl)2, and at least one R3 is an amino group, and when R2 has two R3, the R3 that is an amino group and the -C(O)-(CH2) in R1 m2 - each of the attachment sites in R2 is not in a para position relationship; preferably, each occurrence of R3 is independently selected from F, Cl, Br, I, C 1-3 Alkyl, amino, nitro, hydroxyl, cyano and C 1-3 Alkoxy, and at least one R3 is an amino group, and when R2 has two R3, the amino R3 and the -C(O)-(CH2) in R1 m2 - each of the attachment sites in R2 is not in a para position relationship; preferably, each occurrence of R3 is independently selected from F, Cl, Br, I, C 1-3 Alkyl, and amino, and at least one R3 is amino, when R2 has two R3, the R3 that is amino and -C(O)-(CH2) in R1 m2 - the respective attachment sites in R2 are not in a para relationship; in one embodiment, m2 is 1, 2 or 3; more preferably, m2 is 1.
[0016] In one embodiment, the compound is selected from the following compounds:
[0017] The second aspect of the present invention provides a compound or a pharmaceutically acceptable salt thereof, wherein the compound has the structure DL,
[0018] Wherein, D- has the structure of formula I,
[0019] R A -C(O)-(CH2) m1 R B -NH-;
[0020] R B is a 6-10 membered arylene group, a 5-10 membered heteroarylene group containing 1, 2 or 3 heteroatoms independently selected from N, O and S, a 3-8 membered cycloalkylene group or a 3-8 membered heterocycloalkylene group containing 1, 2 or 3 heteroatoms independently selected from N, O and S, wherein the arylene group, heteroarylene group, cycloalkylene group and heterocycloalkylene group are each independently substituted by 0, 1, 2 or more R C Preferably, the arylene, heteroarylene, cycloalkylene and heterocycloalkylene are each independently substituted by 0, 1, 2, 3, or 4 R C replace;
[0021] R C Each occurrence is independently selected from halogen, C 1-6 Alkyl, C 1-6Haloalkyl, amino, nitro, hydroxy, cyano, C 1-6 Alkoxy, -NH-C 1-6 Alkyl, and -N(C 1-6 Alkyl)2;
[0022] m1 is 1, 2, 3, 4, 5, or 6;
[0023] L has the structure of Formula II:
[0024] n1 is 1, 2, 3, 4, 5, or 6;
[0025] n is 0, 1, 2, 3, 4, 5, 6, 7 or 8;
[0026] n3 is 0, 1, 2, 3, 4, 5, 6, 7 or 8; and
[0027] L a is a peptide residue consisting of 2 to 7 amino acid residues selected from the group consisting of alanine, phenylalanine, glycine, valine, lysine, citrulline, serine, glutamic acid and aspartic acid residues;.
[0028] In one embodiment,
[0029] R A -CO-CH2-R B -NH-; in one embodiment,
[0030] R B 0, 1, 2, 3, or 4 R C substituted 6-10 membered arylene or 5-10 membered heteroarylene containing 1, 2 or 3 heteroatoms independently selected from N, O and S; preferably, R B 0, 1, 2, 3, or 4 R C substituted 6-10 membered arylene; preferably, R B 0, 1, 2, or 3 R C substituted phenylene;
[0031] In one embodiment, R C Each occurrence is independently selected from F, Cl, Br, I, C 1-3 Alkyl, C 1-3 Haloalkyl, amino, nitro, hydroxy, cyano, C 1-3 Alkoxy, -NH-C 1-3 Alkyl, and -N(C 1-3 alkyl)2; preferably, R C Each occurrence is independently selected from F, Cl, Br, I, C 1-3 Alkyl, amino, nitro, hydroxyl, cyano and C1-3 Alkoxy; preferably, R C Each occurrence is independently selected from F, Cl, Br, I, C 1-3 Alkyl, amino and C 1-3 Alkoxy; and / or, m1 is 1, 2 or 3; preferably, m1 is 1; in one embodiment,
[0032] n1 is 1, 2 or 3; preferably, n1 is 1; in one embodiment,
[0033] n is 5, 6 or 7, more preferably n is 6; in one embodiment,
[0034] n3 is 3, 4, 5, 6 or 7, more preferably n3 is 5; in one embodiment,
[0035] L a is a dipeptide residue, a tripeptide residue or a tetrapeptide residue consisting of an amino acid residue selected from alanine, phenylalanine, glycine, valine, lysine, citrulline, serine, glutamic acid, and aspartic acid residues; more preferably L a is a dipeptide residue of valine residue-alanine residue, a tripeptide residue of alanine residue-alanine residue-alanine residue, or a tetrapeptide residue of glycine residue-glycine residue-phenylalanine residue-glycine residue; more preferably L a for
[0036] In one embodiment, it is characterized in that L is n is 5, 6 or 7, and in one embodiment, n is 6.
[0037] In one embodiment,
[0038] D is selected from the following structures:
[0039] In one embodiment, the compound is selected from the following structures:
[0040] wherein n is 0, 1, 2, 3, 4, 5, 6, 7 or 8, preferably, n is 5, 6 or 7, and more preferably, n is 6.
[0041] The third aspect of the present invention provides an antibody-drug conjugate as shown in Formula 3, or a pharmaceutically acceptable salt thereof, characterized in that:
[0042] D is as defined in any of the above items;
[0043] Pc is an antibody or antigen-binding fragment thereof or a polypeptide;
[0044] m is an integer or decimal from 1 to 15;
[0045] L1 has the structure of formula 4:
[0046] n1 is 1, 2, 3, 4, 5, or 6;
[0047] n is 0, 1, 2, 3, 4, 5, 6, 7 or 8;
[0048] n3 is 0, 1, 2, 3, 4, 5, 6, 7 or 8; and
[0049] L a is a peptide residue consisting of 2 to 7 amino acid residues selected from the group consisting of alanine, phenylalanine, glycine, valine, lysine, citrulline, serine, glutamic acid and aspartic acid residues;.
[0050] In one embodiment, it is characterized in that
[0051] m is an integer or decimal from 1 to 10; preferably, m is an integer or decimal from 3 to 9; more preferably, m is an integer or decimal from 6 to 9; and / or
[0052] n1 is 1, 2 or 3; more preferably, n1 is 1; and / or
[0053] n is 5, 6 or 7, more preferably n is 6; and / or
[0054] n3 is 3, 4, 5, 6 or 7, more preferably n3 is 5; and / or
[0055] L a is a dipeptide residue, tripeptide residue or tetrapeptide residue consisting of an amino acid residue selected from alanine, phenylalanine, glycine, valine, lysine, citrulline, serine, glutamic acid and aspartic acid residues; more preferably L a is a dipeptide residue of valine residue-alanine residue, a tripeptide residue of alanine residue-alanine residue-alanine residue, or a tetrapeptide residue of glycine residue-glycine residue-phenylalanine residue-glycine residue; more preferably L a for
[0056] Preferably, L1 is Wherein n is 5, 6, or 7, preferably n is 6.
[0057] In one embodiment, the antibody drug conjugate is selected from
[0058] in,
[0059] n is 0, 1, 2, 3, 4, 5, 6, 7 or 8, preferably, n is 5, 6 or 7, more preferably n is 6; and
[0060] m is an integer or decimal from 1 to 15; preferably, m is an integer or decimal from 1 to 10; preferably, m is an integer or decimal from 3 to 9; more preferably, m is an integer or decimal from 6 to 9.
[0061] In one embodiment, the antibody or antigen-binding fragment thereof is selected from the group consisting of a murine antibody, a chimeric antibody, a humanized antibody, and a fully human antibody;
[0062] Preferably, the antibody or antigen-binding fragment thereof is selected from anti-TROP-2 antibody, anti-HER2 (ErbB2) antibody, anti-EGFR antibody, anti-B7-H3 antibody, anti-c-Met antibody, anti-HER3 (ErbB3) antibody, anti-HER4 (ErbB4) antibody, anti-LIV-1 antibody, anti-ROR1 antibody, anti-CD20 antibody, anti-CD22 antibody, anti-CD30 antibody, anti-CD33 antibody, anti-CD44 antibody, anti-CD56 antibody, anti-CD70 antibody, anti-CD73 antibody, anti-CD105 antibody, anti-CEA antibody, anti-A33 antibody, anti-Cripto antibody, anti-EphA2 antibody, anti-G250 antibody, anti-MUCl antibody, anti-Lewis Y antibody, anti-VEGFR antibody, anti-GPNMB antibody, anti-Integrin antibody, anti-PSMA antibody, anti-Tenascin-C antibody, anti-SLC44A4 antibody and anti-Mesothelin antibody or antigen-binding fragment thereof;
[0063] Preferably, the antibody or antigen-binding fragment thereof is selected from anti-TROP-2 antibodies, anti-HER2 (ErbB2) antibodies, anti-HER3 (ErbB3) antibodies, anti-LIV-1 antibodies and anti-ROR1 antibodies or antigen-binding fragments thereof; preferably, the antibody or antigen-binding fragment thereof is an anti-HER3 antibody or antigen-binding fragment thereof; preferably, the CDR1 of the heavy chain variable region of the anti-HER3 antibody or antigen-binding fragment thereof is shown in SEQ ID NO: 1, the CDR2 of the heavy chain variable region is shown in SEQ ID NO: 2, the CDR3 of the heavy chain variable region is shown in SEQ ID NO: 3, the CDR1 of the light chain variable region is shown in SEQ ID NO: 4, the CDR2 of the light chain variable region is shown in SEQ ID NO: 5, and the CDR3 of the light chain variable region is shown in SEQ ID NO: 6; further preferably, the heavy chain variable region of the antibody or antigen-binding fragment thereof is shown in SEQ ID NO: 7, and the light chain variable region is shown in SEQ ID NO: 8; even further preferably, the heavy chain of the antibody or antigen-binding fragment thereof is shown in SEQ ID NO: 9, and the light chain is shown in SEQ ID NO: 10.
[0064] The fourth aspect of the present invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound as described above or a pharmaceutically acceptable salt thereof, or an antibody-drug conjugate according to any of the foregoing or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, diluent or excipient.
[0065] The present invention also provides a use of the compound or antibody-drug conjugate or a pharmaceutically acceptable salt thereof as described above, or the pharmaceutical composition as described above, in the preparation of a medicament for treating or preventing tumors or cancers; preferably, the tumor or cancer is a tumor or cancer associated with HER3 expression;
[0066] More preferably, the tumor or cancer is breast cancer, colorectal adenocarcinoma, melanoma or lung cancer; further preferably, the cancer associated with HER3 expression is lung cancer.
[0067] The present invention also provides a method for preventing or treating tumors or cancer, comprising administering to a subject in need thereof an effective amount of the compound or antibody-drug conjugate or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 12, or the pharmaceutical composition according to claim 13;
[0068] Preferably, the tumor or cancer is a tumor or cancer associated with HER3 expression;
[0069] More preferably, the tumor or cancer is breast cancer, colorectal adenocarcinoma, melanoma or lung cancer; further preferably, the cancer associated with HER3 expression is lung cancer.
[0070] The present invention also provides the compound or antibody-drug conjugate or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition described above, for use in preventing or treating tumors or cancers;
[0071] Preferably, the tumor or cancer is a tumor or cancer associated with HER3 expression;
[0072] Preferably, the tumor or cancer is breast cancer, colorectal adenocarcinoma, melanoma or lung cancer;
[0073] Preferably, the cancer associated with HER3 expression is lung cancer.
[0074] The present invention also provides a use of the compound as described above or a pharmaceutically acceptable salt thereof, characterized in that the compound is used as a toxin in an antibody-drug conjugate to prepare the antibody-drug conjugate. Beneficial effects
[0075] The compound and antibody-drug conjugate provided by the present invention have strong tumor inhibition efficiency and are suitable for clinical drug application. DETAILED DESCRIPTION
[0076] The following is a clear and complete description of the technical solution of the present invention. Obviously, the embodiments described are only some embodiments of the present invention, not all embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without making any creative efforts are within the scope of protection of the present invention.
[0077] Terms and Definitions
[0078] Unless otherwise defined below, all technical and scientific terms used herein are intended to have the same meanings as commonly understood by one of ordinary skill in the art.
[0079] Certain compounds of the present invention may exist in free form or, where appropriate, in the form of pharmaceutically acceptable derivatives thereof. In the present invention, pharmaceutically acceptable derivatives include, but are not limited to, pharmaceutically acceptable salts, prodrugs, stereoisomers (including but not limited to diastereomers and enantiomers), tautomers, solvates, polymorphs and isotopic compounds, which, after being administered to a patient in need thereof, can directly or indirectly provide a compound of the present invention or a metabolite thereof. Therefore, when referring to a "compound of the present invention" herein, it is also intended to encompass the various derivative forms of the compound described above.
[0080] The term "pharmaceutically acceptable salt" refers to a salt that retains the biological effectiveness of the free acids and bases of the specified compound without any adverse biological effects. Examples of pharmaceutically acceptable salts include, but are not limited to: (1) acid addition salts, such as salts formed with inorganic acids such as hydrochloric acid, sulfuric acid, hydrobromic acid, nitric acid, phosphoric acid, etc.; or salts formed with organic acids such as malic acid, fumaric acid, maleic acid, benzoic acid, phenylacetic acid, succinic acid, tartaric acid, citric acid, methanesulfonic acid, ethanesulfonic acid, glycolic acid, cinnamic acid, pyruvic acid, formic acid, acetic acid, propionic acid, oxalic acid, malonic acid, acrylic acid, mandelic acid, etc.; or (2) base addition salts, such as salts formed with alkali metals such as lithium, sodium, potassium, etc.; and salts formed with alkaline earth metals such as calcium, magnesium, etc.; and salts formed with organic bases such as ammonium, choline, diethanolamine, lysine, ethylenediamine, tert-butylamine, tert-octylamine, tris(hydroxymethyl)aminomethane, N-methylglucamine, triethanolamine, dehydroabietinamine, etc. Other pharmaceutically acceptable salts are known to those skilled in the art.
[0081] Prodrugs of the compounds of the present invention are included within the scope of protection of the present invention. Generally, prodrugs are functional derivatives that are easily converted into the desired compound in vivo. Therefore, the term "administering" in the treatment methods provided herein includes administering the compounds disclosed herein, or methods that, although not explicitly disclosed, can be converted into the compounds disclosed herein in vivo after administration to a subject to treat the various diseases described. Conventional methods for selecting and preparing suitable prodrug derivatives are described in books such as "Design of Prodrugs" (H. Bundgaard, Elsevier, 1985).
[0082] The compounds of the present invention may contain one or more asymmetric centers and may thus produce diastereomers and optical isomers. The present invention includes all possible diastereomers and racemic mixtures thereof, their substantially pure resolved enantiomers, all possible geometric isomers and pharmaceutically acceptable salts thereof.
[0083] The compounds of the present invention do not have a precise stereostructure at any particular position within the compounds. The present invention encompasses all stereoisomers of the compounds and pharmaceutically acceptable salts thereof. Furthermore, mixtures of stereoisomers and isolated specific stereoisomers are also encompassed by the present invention. During the synthetic process for preparing such compounds, or using racemization or epimerization methods known to those skilled in the art, the resulting products may be mixtures of stereoisomers.
[0084] When the compounds of the present invention exist in tautomers, unless otherwise stated, the present invention includes any possible tautomers and pharmaceutically acceptable salts thereof, and mixtures thereof.
[0085] When the compounds of the present invention and their pharmaceutically acceptable salts exist in the form of solvates or polymorphs, the present invention includes any possible solvates and polymorphs. The type of solvent used to form the solvate is not particularly limited, as long as the solvent is pharmacologically acceptable. For example, water, ethanol, propanol, acetone and the like can be used.
[0086] The present invention also includes all pharmaceutically acceptable isotopic compounds that are identical to the compounds of the present invention except that one or more atoms are replaced by an atom having the same atomic number but an atomic mass or mass number different from the atomic mass or mass number prevalent in nature. Examples of suitable isotopes for inclusion in the compounds of the present invention include, but are not limited to, isotopes of hydrogen (e.g., deuterium (2H), tritium (3H)); isotopes of carbon (e.g., 13C and 14C); isotopes of chlorine (e.g., 37Cl); isotopes of iodine (e.g., 125I); isotopes of nitrogen (e.g., 13N and 15N); isotopes of oxygen (e.g., 17O and 18O); isotopes of phosphorus (e.g., 32P); and isotopes of sulfur (e.g., 34S).
[0087] The term "ligand" refers to a macromolecular compound that recognizes and binds to an antigen or receptor associated with a target cell. The function of a ligand is to present a drug to the target cell population bound to the ligand. In embodiments of the present invention, the ligand is represented by Pc. The ligand can form a linker bond with a linker through a heteroatom on the ligand. The ligand is preferably an antibody, antigen-binding fragment thereof, or polypeptide. The antibody is selected from a chimeric antibody, a humanized antibody, a fully human antibody, or a murine antibody; preferably, a monoclonal antibody.
[0088] The term "drug" refers to a cytotoxic drug, represented by D, which is a chemical molecule that has a strong ability to disrupt the normal growth of tumor cells.
[0089] The term "linker unit," "linking fragment," "linking unit," "linking moiety," or "linker" refers to a chemical structure fragment or bond that connects to a ligand at one end and to a drug at the other end. It may also be connected to another linker before being connected to the drug. In the practice of the present invention, the linker unit is represented by L or L1.
[0090] The term "ligand-drug conjugate" refers to a ligand linked to a biologically active drug via a stable linker. In the present disclosure, a "ligand-drug conjugate" is preferably an antibody-drug conjugate (ADC) or antibody-drug conjugate, which refers to a monoclonal antibody or antibody fragment linked to a biologically active toxic drug via a stable linker.
[0091] The three letter and one letter codes for amino acids used in this disclosure are as described in J. biol. chem, 243, p3558 (1968).
[0092] The term "antibody" refers to immunoglobulins, which are tetrapeptide chains composed of two identical heavy chains and two identical light chains connected by interchain disulfide bonds. The amino acid composition and order of the constant region of immunoglobulins' heavy chains vary, resulting in different antigenicity. Consequently, immunoglobulins can be divided into five classes, or isotypes, namely IgM, IgD, IgG, IgA, and IgE, with their corresponding heavy chains being μ, δ, γ, α, and ε, respectively. Within the same class, Igs are further divided into subclasses based on the amino acid composition of their hinge regions and the number and location of heavy chain disulfide bonds. For example, IgG can be divided into IgG1, IgG2, IgG3, and IgG4. Light chains are classified as either kappa or lambda chains based on differences in their constant regions. Each of the five Ig classes can have either kappa or lambda chains. The antibodies disclosed herein are preferably specific antibodies against cell surface antigens on target cells, and non-limiting examples thereof include the following antibodies: anti-TROP-2 antibody, anti-HER2 (ErbB2) antibody, anti-EGFR antibody, anti-B7-H3 antibody, anti-c-Met antibody, anti-HER3 (ErbB3) antibody, anti-HER4 (ErbB4) antibody, anti-LIV-1 antibody, anti-ROR1 antibody, anti-CD20 antibody, anti-CD22 antibody, anti-CD30 antibody, anti-CD33 antibody, anti-CD44 antibody, anti-CD56 antibody, anti-CD70 antibody, anti-CD73 antibody, anti-CD105 antibody, anti-CEA antibody, anti-A33 antibody, anti-Cripto antibody, anti-EphA2 antibody, anti-G250 antibody, anti-MUCl antibody, anti-Lewis antibody. Y antibody, anti-VEGFR antibody, anti-GPNMB antibody, anti-Integrin antibody, anti-PSMA antibody, anti-Tenascin-C antibody, anti-SLC44A4 antibody, anti-Mesothelin antibody or an antigen-binding fragment thereof; more preferably, the antibody or antigen-binding fragment thereof is an anti-HER2 (ErbB2) antibody or an antigen-binding fragment thereof; most preferably, the antibody or antigen-binding fragment thereof is trastuzumab.
[0093] The antibodies of the present invention include murine antibodies, chimeric antibodies, humanized antibodies and fully human antibodies, with humanized antibodies and fully human antibodies being preferred.
[0094] The term "murine antibody" as used herein refers to antibodies produced in mice according to the knowledge and skills in the art. During production, a test subject is injected with a specific antigen and then a hybridoma expressing an antibody with the desired sequence or functional properties is isolated.
[0095] The term "chimeric antibody" refers to an antibody created by fusing the variable region of a mouse antibody with the constant region of a human antibody, which can mitigate the immune response induced by the mouse antibody. To create a chimeric antibody, one must first establish a hybridoma that secretes mouse-specific monoclonal antibodies. The variable region genes are then cloned from the mouse hybridoma cells. Furthermore, the constant region genes of the human antibody are cloned as needed. The mouse variable region genes and the human constant region genes are then linked to form a chimeric gene, which is then inserted into an expression vector. Finally, the chimeric antibody molecule is expressed in a eukaryotic or prokaryotic system.
[0096] The term "humanized antibody," also known as a CDR-grafted antibody, refers to an antibody produced by grafting murine CDR sequences onto a human variable region framework, i.e., different types of human germline antibody framework sequences. This overcomes the xenobiotic response induced by chimeric antibodies due to the presence of a large amount of murine protein.
[0097] The terms "fully human antibody", "fully human antibody" or "completely human antibody", also known as "fully human monoclonal antibody", refer to antibodies whose variable and constant regions are both human, eliminating immunogenicity and toxic side effects.
[0098] The term "antigen-binding fragment" refers to one or more fragments of an antibody that retain the ability to specifically bind to an antigen. It has been shown that fragments of a full-length antibody can be used to perform the antigen-binding function of an antibody. Examples of binding fragments included in "antigen-binding fragments" include (i) a Fab fragment, a monovalent fragment consisting of the VL, VH, CL, and CH1 domains; (ii) a F(ab')2 fragment, a bivalent fragment comprising two Fab fragments connected by a disulfide bridge on the hinge region, (iii) a Fd fragment consisting of the VH and CH1 domains; (iv) an Fv fragment consisting of the VH and VL domains of a single arm of an antibody; (v) a single domain or dAb fragment (Ward et al., (1989) Nature 341: 544-546), which consists of the VH domain; and (vi) an isolated complementarity determining region (CDR) or (vii) a combination of two or more isolated CDRs, optionally connected by a synthetic linker. In addition, although the two domains VL and VH of the Fv fragment are encoded by separate genes, they can be connected by synthetic linkers using recombinant methods, so that they can be produced as a single protein chain in which the VL and VH regions are paired to form a monovalent molecule (called single-chain Fv (scFv); see, for example, Bird et al. (1988) Science 242: 423-426; and Huston et al. (1988) Proc. Natl. Acad. Sci USA 85: 5879-5883). Such single-chain antibodies are also intended to be included in the term "antigen-binding fragment" of an antibody. Such antibody fragments are obtained using conventional techniques known to those skilled in the art, and the fragments are screened for functionality in the same manner as for intact antibodies. Antigen-binding portions can be produced by recombinant DNA technology or by enzymatic or chemical fragmentation of intact immunoglobulins.
[0099] Fab is an antibody fragment having a molecular weight of approximately 50,000 and antigen-binding activity, among fragments obtained by treating IgG antibody molecules with the protease papain (cleaving the amino acid residue at position 224 of the H chain), in which approximately half of the N-terminal side of the H chain and the entire L chain are bound together by a disulfide bond.
[0100] F(ab')2 is an antibody fragment having a molecular weight of about 100,000 and antigen-binding activity, obtained by digesting the portion below the two disulfide bonds in the hinge region of IgG with the enzyme pepsin, and comprises two Fab regions linked at the hinge position.
[0101] Fab' is an antibody fragment having a molecular weight of about 50,000 and antigen-binding activity, obtained by cleaving the disulfide bond of the hinge region of the above-mentioned F(ab')2.
[0102] Furthermore, the Fab' fragment of the antibody can be produced by inserting a DNA encoding the Fab' fragment into a prokaryotic expression vector or a eukaryotic expression vector and introducing the vector into a prokaryotic or eukaryotic organism to express the Fab'.
[0103] The term "single-chain antibody", "single-chain Fv" or "scFv" refers to a molecule comprising an antibody heavy chain variable domain (or region; VH) and an antibody light chain variable domain (or region; VL) connected by a linker. Such scFv molecules can have the general structure: NH2-VL-linker-VH-COOH or NH2-VH-linker-VL-COOH. Suitable prior art linkers consist of repeated GGGGS amino acid sequences or variants thereof, for example, variants using 1-4 repeats (Holliger et al. (1993), Proc. Natl. Acad. Sci. USA 90: 6444-6448). Other linkers useful in the present disclosure are described by Alfthan et al. (1995), Protein Eng. 8:725-731, Choi et al. (2001), Eur. J. Immunol. 31:94-106, Hu et al. (1996), Cancer Res. 56:3055-3061, Kipriyanov et al. (1999), J. Mol. Biol. 293:41-56, and Roovers et al. (2001), Cancer Immunol.
[0104] The term "CDR" refers to one of the six hypervariable regions in the variable domain of an antibody that primarily contributes to antigen binding. One of the most commonly used definitions of the six CDRs is provided by Kabat EA et al. (1991) Sequences of proteins of immunological interest. NIH Publication 91-3242). As used herein, the Kabat definition of CDR applies only to CDR1, CDR2, and CDR3 (CDR L1, CDR L2, CDR L3, or L1, L2, L3) of the light chain variable domain, and CDR2 and CDR3 (CDR H2, CDR H3, or H2, H3) of the heavy chain variable domain.
[0105] The term "vector" refers to a nucleic acid molecule capable of transporting another nucleic acid connected thereto. In one embodiment, a vector is a "plasmid", which refers to a circular double-stranded DNA loop into which another DNA segment can be connected. In another embodiment, a vector is a viral vector, in which another DNA segment can be connected to a viral genome. Vectors disclosed herein can autonomously replicate in the host cell into which they have been introduced (e.g., bacterial vectors and additional mammalian vectors with a bacterial origin of replication) or can be integrated into the genome of the host cell after introducing the host cell, thereby replicating (e.g., non-additional mammalian vectors) with the host genome.
[0106] The term "alkyl" refers to a saturated aliphatic hydrocarbon group, which is a straight or branched chain group containing 1 to 20 carbon atoms, preferably an alkyl group containing 1 to 12 carbon atoms, more preferably an alkyl group containing 1 to 10 carbon atoms, and most preferably an alkyl group containing 1 to 6 carbon atoms. The term "C1-6 alkyl" refers to a saturated straight or branched chain hydrocarbon group having 1 to 6 carbon atoms (e.g., 1, 2, 3, 4, 5, or 6 carbon atoms). For example, "C1-6 alkyl" can be methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, or n-hexyl, etc.
[0107] The term "cycloalkyl" refers to a saturated or partially unsaturated monocyclic or polycyclic hydrocarbon substituent, wherein the cycloalkyl ring contains 3 to 20 carbon atoms, preferably 3 to 12 carbon atoms, more preferably 3 to 10 carbon atoms, and most preferably 3 to 8 carbon atoms. Non-limiting examples of monocyclic cycloalkyls include cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cyclohexadienyl, cycloheptyl, cycloheptatrienyl, cyclooctyl, and the like; polycyclic cycloalkyls include spirocyclic, fused, and bridged cycloalkyls.
[0108] The term "heterocyclyl" refers to a saturated or partially unsaturated monocyclic or polycyclic hydrocarbon substituent containing 3 to 20 ring atoms, wherein one or more (e.g., 1, 2, or 3) ring atoms are selected from nitrogen, oxygen, or sulfur, and the remaining ring atoms are carbon. Preferably, it contains 3 to 12 ring atoms, of which 1 to 4 are heteroatoms; more preferably, the cycloalkyl ring contains 3 to 10 ring atoms. Non-limiting examples of monocyclic heterocyclyls include pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, homopiperazinyl, and the like. Polycyclic heterocyclyls include spirocyclic, fused, and bridged heterocyclyls.
[0109] The term "aryl" refers to a 6- to 14-membered all-carbon monocyclic or fused polycyclic (i.e., rings sharing adjacent pairs of carbon atoms) group having a conjugated π electron system, preferably 6- to 10-membered, such as phenyl and naphthyl, with phenyl being preferred. The aryl ring may be fused to a heteroaryl, heterocyclyl, or cycloalkyl ring, wherein the ring attached to the parent structure is the aryl ring.
[0110] The term "heteroaryl" refers to a heteroaromatic system containing 1 to 4 heteroatoms and 5 to 14 ring atoms, wherein the heteroatoms are selected from oxygen, sulfur, and nitrogen. The heteroaryl group is preferably 5- to 10-membered, more preferably 5- or 6-membered, such as furanyl, thienyl, pyridyl, pyrrolyl, N-alkylpyrrolyl, pyrimidinyl, pyrazinyl, imidazolyl, tetrazolyl, and the like. The heteroaryl ring may be fused to an aryl, heterocyclyl, or cycloalkyl ring, wherein the ring attached to the parent structure is the heteroaryl ring.
[0111] The term "haloalkyl" refers to an alkyl group substituted with one or more halogens.
[0112] The term "deuterated alkyl" refers to an alkyl group substituted with one or more deuterium atoms.
[0113] The term "halogen" refers to fluorine, chlorine, bromine or iodine.
[0114] The term "drug moiety" or "D" generally refers to any compound that has the desired biological activity and a reactive functional group for preparing the conjugates of the present invention.
[0115] The terms "substituted" and "substituted" mean that one or more (e.g., one, two, three, or four) hydrogen atoms on the designated atom are replaced with a group selected from the indicated group, provided that the designated atom's normal valency in the present context is not exceeded and that the substitution results in a stable compound. Combinations of substituents and / or variables are permissible only if such combinations result in stable compounds.
[0116] If a substituent is described as "optionally substituted with...", the substituent may be (1) unsubstituted, or (2) substituted. If an atom or group is described as optionally substituted with one or more of the substituents listed, one or more hydrogen atoms on the atom or group may be replaced with independently selected, optional substituents. If a substituent is described as "independently selected from" or "each independently is," each substituent is selected independently of the others. Thus, each substituent may be the same as or different from another substituent. For example, when a substituent or substitution position or different substituents or substitution positions have R groups (such as, but not limited to, R2, R3, Rh, Ri, Rx, and / or Ry) that may be designated by the same or different symbols, each R is selected independently of the others, i.e., may be the same or different. The same is true for the selection of numerical values such as d, g, m, and n.
[0117] Unless otherwise indicated, as used herein, the point of attachment of a substituent may be from any suitable position of the substituent.
[0118] The terms "include," "comprising," "having," "containing," or "involving," and their variations herein, are inclusive or open-ended and do not exclude other unrecited elements or method steps. Those skilled in the art will understand that the above terms, such as "comprising," encompass the meaning of "consisting of."
[0119] As used herein, a "pharmaceutically acceptable carrier" refers to a diluent, adjuvant, excipient, or vehicle with which the active ingredient is administered and which is suitable, within the scope of sound medical judgment, for contact with the tissues of humans and / or other animals without excessive toxicity, irritation, allergic response, or other problems or complications commensurate with a reasonable benefit / risk ratio. The terms "active ingredient," "therapeutic agent," "active substance," or "active agent" refer to a chemical entity that is effective in treating one or more symptoms of a target disorder or condition.
[0120] As used herein, the term "effective amount" (e.g., "therapeutically effective amount" or "prophylactically effective amount") refers to an amount of active ingredient that, upon administration, will achieve the desired effect to a certain extent, such as alleviating one or more symptoms of the condition being treated or preventing the appearance of the condition or its symptoms. Unless otherwise indicated, as used herein, the term "treat" means to reverse, alleviate, inhibit the progression of, or prevent the condition or one or more symptoms of the condition or condition to which the term applies.
[0121] The experimental methods in the following examples are conventional methods unless otherwise specified. The chemical raw materials, reagents, etc. used in the following examples are commercially available products unless otherwise specified. The abbreviations and their meanings appearing in this article are as follows:
[0122] Unless otherwise stated, the cell strains or cell lines used in the examples of the present invention can be obtained through commercial channels.
[0123] SW620 cell line was purchased from Nanjing Kebai Biotechnology Co., Ltd.;
[0124] A375 cell line was purchased from ATCC (American type culture collection);
[0125] NCI-H358 cell line was purchased from ATCC;
[0126] HCC1569 cell line, purchased from ATCC:
[0127] Example 1
[0128] Synthesis of compound 1b:
[0129] EXD (25 mg, 47 μmol, 1 eq) and compound 1a (11.8 mg, 47 μmol, 1 eq) were dissolved in DMF (1 mL). HATU (26.8 mg, 70 μmol, 1.5 eq) and DIEA (19 μL, 118 μmol, 2.5 eq) were added and stirred at room temperature for 2 hours. The reaction mixture was directly purified by reverse-phase column chromatography (63% CH3CN in H2O, 0.05% HCOOH) to obtain a white solid (22 mg, 70%). MS (ESI): m / z found [M-55] + =613.2
[0130] Synthesis of Example 1:
[0131] Compound 24b (22 mg, 33 μmol) was dissolved in trifluoroacetic acid (0.4 mL) and dichloromethane (2 mL) and stirred at room temperature for 2.5 hours. The product was concentrated and purified by reverse phase column chromatography (35% CH3CN in H2O, 0.1% TFA) to afford a yellow solid (14.4 mg, 64% yield). MS (ESI): m / z found [M+1] + =569.2.
[0132] Example 2
[0133] Example 2 (8 mg, yield 41%) was obtained using a similar synthetic route as Example 1. The difference was that compound 1a was replaced by MS(ESI):m / z found[M+1] + =587.2.
[0134] Example 3
[0135] Example 3 (22 mg, yield 44%) was obtained by a similar synthetic route as Example 1, except that compound 1a was replaced by MS(ESI):m / z found[M+1] + =587.2.
[0136] Example 4
[0137] Example 4 (14 mg, yield 28%) was obtained by a similar synthetic route as Example 1, except that compound 1a was replaced by MS(ESI):m / z found[M+1] + =587.2.
[0138] Example 5
[0139] Example 5 (30 mg, yield 66%) was obtained by a similar synthetic route as Example 1, except that compound 1a was replaced by MS(ESI):m / z found[M+1] + =587.2.
[0140] Example 6
[0141] Synthesis of compound 6b:
[0142] Compound 6a (50 mg, 0.33 mmol, 1.0 eq) was dissolved in methanol (1 mL), (Boc)2O (0.5 mL) was added, and the mixture was stirred at room temperature for 6 hours. The reaction mixture was purified by column chromatography (25% EA in PE) to obtain a white solid (75 mg, 90%). MS (ESI): m / z found [M-1] - =250.2 Synthesis of compound 6c:
[0143] EXD (25 mg, 47 μmol, 1 eq) and compound 6b (11.8 mg, 47 μmol, 1 eq) were dissolved in DMF (1 mL). HATU (26.8 mg, 70 μmol, 1.5 eq) and DIEA (19 μL, 118 μmol, 2.5 eq) were added and stirred at room temperature for 2 hours. The reaction mixture was directly purified by reverse-phase column chromatography (63% CH3CN inH2O, 0.05% HCOOH) to obtain a white solid (20 mg, 64%). MS (ESI): m / z found [M-55] + =613.2
[0144] Synthesis of Example 6:
[0145] Compound 6c (20 mg, 30 μmol) was dissolved in trifluoroacetic acid (0.4 mL) and dichloromethane (2 mL) and stirred at room temperature for 2.5 hours. The mixture was concentrated and purified by reverse phase column chromatography (35% CH3CN in H2O, 0.1% TFA) to afford compound 6 (14 mg, 70%) as a yellow solid. MS (ESI): m / z found [M+1] + =569.2.
[0146] Example 7
[0147] Example 7 (22 mg, yield 45%) was obtained by a similar synthetic route as Example 6, except that compound 6b was replaced by MS(ESI):m / z found[M+1]+ =587.2.
[0148] Example 8
[0149] A similar synthetic route was used as in Example 6, except that compound 6b was replaced by Example 8 (45 mg, yield 66%) was obtained. MS (ESI): m / z found [M+1] + =587.2.
[0150] Example 9
[0151] A similar synthetic route was used as in Example 6, except that compound 6b was replaced by Example 9 (35 mg, yield 56%) was obtained. MS (ESI): m / z found [M+1] + =587.2.
[0152] Example 10
[0153] A similar synthetic route was used as in Example 6, except that compound 6b was replaced by Example 10 (47 mg, yield 50%) was obtained. MS (ESI): m / z found [M+1] + =587.2.
[0154] Example 11
[0155] Synthesis of compound 11b:
[0156] p-Aminophenylacetic acid 11a (617 mg, 4.08 mmol, 1.0 eq) was dissolved in dioxane (8 mL) and water (4 mL). 1N sodium bicarbonate (4 mL) and (Boc)2O (980 mg, 4.49 mmol, 1.1 eq) were added and stirred at room temperature for 24 hours. The reaction mixture was neutralized with 2N hydrochloric acid, diluted with 50 mL of water, extracted with ethyl acetate, washed with saturated brine, dried, concentrated, and purified by column chromatography (25% EA in PE) to afford a white solid (700 mg, 68%). MS (ESI): m / z found [M-1] = 250.0.
[0157] Synthesis of compound 11c:
[0158] EXD (25 mg, 47 μmol, 1.0 eq) and compound 11b (11.8 mg, 47 μmol, 1.0 eq) were dissolved in DMF (1 mL). HATU (26.8 mg, 70 μmol, 1.5 eq) and DIEA (19 μL, 118 μmol, 2.5 eq) were added and stirred at room temperature for 2 hours. Water was added and the mixture was extracted with ethyl acetate. The organic phase was washed with saturated brine, dried, concentrated, and purified by column chromatography (4% MeOH in CH2Cl2) to give a white solid (27 mg, 86%). MS (ESI): m / z found [M+1] + =669.2.
[0159] Synthesis of Example 11:
[0160] Compound 11c (27 mg, 40 μmol) was dissolved in trifluoroacetic acid (0.4 mL) and dichloromethane (2 mL) and stirred at room temperature for 2.5 hours. The mixture was concentrated and purified by reverse phase column chromatography (31% CH3CN in H2O, 0.1% TFA) to give compound 11 (19 mg, 70%) as a yellow solid. MS (ESI): m / z found [M+1] + =569.2.
[0161] Example 12
[0162] A similar synthetic route was used as in Example 11, except that compound 11b was replaced by Example 12 (56 mg, yield 44%) was obtained. MS (ESI): m / z found [M+1] + =587.2.
[0163] Example 13
[0164] A similar synthetic route was used as in Example 11, except that compound 11b was replaced by Example 13 (30 mg, yield 40%) was obtained. MS (ESI): m / z found [M+1] + =587.2.
[0165] Example 14
[0166] Example 14 (39 mg, yield 23%) was obtained by a similar synthetic route as Example 11, except that compound 11b was replaced by MS(ESI):m / z found[M+1] + =603.2.
[0167] Example 15
[0168] Example 15 (56 mg, yield 61%) was obtained by a similar synthetic route as Example 11, except that compound 11b was replaced by MS(ESI):m / z found[M+1] + =605.2.
[0169] Example 16
[0170] Example 16 (40 mg, yield 33%) was obtained by a similar synthetic route as Example 6, except that compound 6b was replaced by MS(ESI):m / z found[M+1] + =605.2.
[0171] Example 17
[0172] Example 17 (45 mg, yield 31%) was obtained by a similar synthetic route as Example 11, except that compound 11b was replaced by MS(ESI):m / z found[M+1] + =599.2.
[0173] Example 18
[0174] Example 18 (57 mg, yield 43%) was obtained by a similar synthetic route as Example 11, except that compound 11b was replaced by MS(ESI):m / z found[M+1] + =605.2.
[0175] Example 19
[0176] Example 19 (23 mg, yield 33%) was obtained by a similar synthetic route as Example 1, except that compound 1a was replaced by MS(ESI):m / z found[M+1] + =621.2.
[0177] Example 20
[0178] Example 20 (23 mg, yield 33%) was obtained by a similar synthetic route as Example 1, except that compound 1a was replaced by MS(ESI):m / z found[M+1] + =605.2.
[0179] Example 21
[0180] Example 21 (43 mg, yield 35%) was obtained by a similar synthetic route as Example 11, except that compound 11b was replaced by MS(ESI):m / z found[M+1] + =605.2.
[0181] Example 22
[0182] Synthesis of compound 22b:
[0183] Compound 22a (2.0 g, 11.05 mmol, 1.0 eq), DMAP (700 mg, 5.74 mmol, 0.5 eq), and (Boc)2O (5.2 mL, 2.0 eq) were added to t-BuOH (20 mL) at room temperature. After 4 h of reaction, TLC analysis indicated the reaction was complete. The reaction solution was purified on a silica gel column (EA / PE = 5%) to obtain compound 22b (2.0 g, 87%). MS (ESI): m / z found [M+23] + =260
[0184] Synthesis of compound 22c:
[0185] Compound 22b (2.0 g, 8.44 mmol, 1.0 eq) and Fe (2.36 g, 42.14 mmol, 5.0 eq) were added to a solution of EtOH (10 mL) and saturated NH4Cl (10 mL) at room temperature. The reaction solution was heated to 90°C and allowed to react for 3 h. LCMS analysis indicated the reaction was complete. The reaction solution was extracted with EA, and the organic phase was washed with saturated brine. The organic phase was dried to give the crude product, which was then purified on a C18 column (ACN / H2O = 50%) to afford compound 22c (477 mg, 27%). MS (ESI): m / z found [M-55] + =152
[0186] Synthesis of compound 22d:
[0187] Compound 22c (477 mg, 2.30 mmol, 1.0 eq) and pyridine (932 μL, 5.0 eq) were added to DMF (5 mL). Phenyl chloroformate (578 μL, 2.0 eq) was slowly added to the reaction mixture under an ice bath. After 4 h of reaction, LCMS analysis indicated completion. The mixture was extracted with EA, washed with saturated brine, and the organic phase was dried and purified on a silica gel column (EA / PE = 10%) to obtain compound 22d (730 mg, 97%). MS (ESI): m / z found [M-55] + =272
[0188] Synthesis of compound 22f:
[0189] Compound 22d (730 mg, 2.23 mmol, 1.2 eq) and compound 22e (547 mg, 1.86 mmol, 1.0 eq) were added to DMF (7 mL). The reaction solution was cooled in an ice bath, and then NaH (149 mg, 3.73 mmol, 2.0 eq) was slowly added to the reaction solution. After 1 h of reaction, LCMS analysis indicated the reaction was complete. The product was extracted with EA, and the organic phase was dried and purified on a silica gel column (EA / PE = 22%) to obtain compound 22f (485 mg, 49%).
[0190] Synthesis of compound 22g:
[0191] Compound 22f (485 mg, 0.920 mmol, 1.0 eq) and TFA (1 mL) were added to DCM (5 mL) at room temperature. After 2 h of reaction, LCMS analysis indicated the reaction was complete. Purification by C18 column afforded compound 22g (341 mg, 100%). MS (ESI): m / z found [M-1] - =370.
[0192] Synthesis of compound 22i:
[0193] Compound 22g (375 mg, 0.919 mmol, 1.0 eq), compound 22h (341 mg, 0.919 mmol, 1.0 eq), and DIEA (408 μL, 6.0 eq) were added to THF (4 mL) at room temperature. After 17 h of reaction, LCMS analysis indicated the reaction was complete. The reaction solution was purified on a silica gel column (MeOH / DCM = 5% to 10%) to yield compound 22i (631 mg, 100%). MS (ESI): m / z found [M-1] - =663.
[0194] Synthesis of compound 22j:
[0195] Compound 10 (631 mg, 0.950 mmol, 1.0 eq) and Et2NH (1.2 mL) were added to ACN (6 mL) at room temperature. After 7 h of reaction, LCMS analysis indicated the reaction was complete. Purification by C18 column (ACN / H2O = 16%) afforded compound 22j (171 mg, 41%). MS (ESI): m / z found [M+1] + =443.
[0196] Synthesis of compound 221:
[0197] Compound 22j (143 mg, 0.350 mmol, 1.1 eq), compound 22h (141 mg, 0.319 mmol, 1.0 eq), and DIEA (94 μL, 2.0 eq) were added to DMF (2 mL) at room temperature. After 1.5 h of reaction, LCMS analysis indicated completion. Et2NH (0.4 mL) was added to the reaction solution. After 2 h of reaction, LCMS analysis indicated completion. The reaction mixture was purified on a C18 column (ACN / H2O = 13%) to obtain compound 22l (166 mg, 92%). MS (ESI): m / z found [M+1] + =514.
[0198] Synthesis of compound 22o:
[0199] Compound 221 (238 mg, 0.354 mmol, 1.1 eq), compound 22m (165 mg, 0.322 mmol, 1.0 eq), and DIEA (95 μL, 2.0 eq) were added to DMF (2 mL) at room temperature. After 2 h of reaction, LCMS analysis indicated completion. Et2NH (0.5 mL) was added to the reaction solution. After 1 h of reaction, LCMS analysis indicated completion. The reaction mixture was purified via a C18 column (ACN / H2O = 11% to 22%) to yield compound 22o (137 mg, 50%). MS (ESI): m / z found [M+1] + =849.
[0200] Synthesis of compound 22q:
[0201] Compound 22o (53 mg, 0.172 mmol, 1.2 eq), 22p (122 mg, 0.144 mmol, 1.0 eq), and DIEA (64 μL, 3.0 eq) were added to a DMF (1.5 mL) solution at room temperature. After 1 h of reaction, LCMS analysis indicated the reaction was complete. The reaction solution was purified on a C18 column (ACN / H2O (0.05% HCOOH) = 32%) to afford compound 22q (16.7 mg, 9%). MS (ESI): m / z found [M / 2+1] + =424 / 591 / 847.
[0202] Synthesis of Example 22:
[0203] Compound 19 (16.7 mg, 0.016 mmol, 1.0 eq), EXD (8.5 mg, 0.016 mmol, 1.0 eq), HATU (7.3 mg, 0.019 mmol, 1.2 eq), and DIEA (7 μL, 3.0 eq) were added to DMF (1 mL) at room temperature. After 1 h of reaction, LCMS analysis indicated the reaction was complete. The reaction solution was diluted with acetonitrile and purified by HPLC to afford compound 22 (6 mg, 26%). MS (ESI): m / z found [M / 2+1] + =730.
[0204] Example 23
[0205] Example 23 (48 mg, 32% yield) was obtained by a similar synthetic route as Example 22, except that compound 22a was replaced by MS(ESI):m / z found[M / 2+1] + =739
[0206] Example 24
[0207] Example 24 (32 mg, yield 25%) was obtained by a similar synthetic route as Example 22, except that compound 22a was replaced by MS(ESI):m / z found[M / 2+1] + =739
[0208] Example 25
[0209] Example 25 (32 mg, yield 27%) was obtained by a similar synthetic route as Example 22, except that compound 22a was replaced by MS(ESI):m / z found[M / 2+1] + =739
[0210] Example 26
[0211] Example 26 (53 mg, yield 36%) was obtained by a similar synthetic route as Example 22, except that compound 22a was replaced by MS(ESI):m / z found[M / 2+1] + =739
[0212] Example 27
[0213] Example 27 (28 mg, yield 20%) was obtained by a similar synthetic route as Example 22, except that compound 22a was replaced by MS(ESI):m / z found[M / 2+1] + =730
[0214] Example 28
[0215] Example 28 (6 mg, yield 13%) was obtained by a similar synthetic route as Example 22, except that compound 22a was replaced by MS(ESI):m / z found[M / 2+1] + =739
[0216] Example 29
[0217] Example 29 (14 mg, 6% yield) was obtained by a similar synthetic route as Example 22, except that compound 22a was replaced by MS(ESI):m / z found[M / 2+1] + =739
[0218] Example 30
[0219] Example 30 (20 mg, yield 13%) was obtained by a similar synthetic route as Example 22, except that compound 22a was replaced by MS(ESI):m / z found[M / 2+1] + =739
[0220] Example 31
[0221] Example 31 (36 mg, 32% yield) was obtained by a similar synthetic route as Example 22, except that compound 22a was replaced by MS(ESI):m / z found[M / 2+1] + =730
[0222] Example 32
[0223] Example 32 (17 mg, yield 17%) was obtained by a similar synthetic route as Example 22, except that compound 22a was replaced by MS(ESI):m / z found[M / 2+1] + =739
[0224] Example 33
[0225] Example 33 (43 mg, yield 31%) was obtained by a similar synthetic route as Example 22, except that compound 22a was replaced by MS(ESI):m / z found[M / 2+1] + =739
[0226] Example 34
[0227] Example 34 (32 mg, yield 26%) was obtained by a similar synthetic route as Example 22, except that compound 22a was replaced by MS(ESI):m / z found[M / 2+1] + =747
[0228] Example 35
[0229] Example 35 (14 mg, 6% yield) was obtained by a similar synthetic route as Example 22, except that compound 22a was replaced by MS(ESI):m / z found[M / 2+1] + =748
[0230] Example 36
[0231] Example 36 (15 mg, yield 20%) was obtained by a similar synthetic route as Example 22, except that compound 22a was replaced by MS(ESI):m / z found[M / 2+1] + =748
[0232] Example 37
[0233] Example 37 (19 mg, 9% yield) was obtained by a similar synthetic route as Example 22, except that compound 22a was replaced by MS(ESI):m / z found[M / 2+1] + =745
[0234] Example 38
[0235] Example 38 (11 mg, yield 12%) was obtained by a similar synthetic route as Example 22, except that compound 22a was replaced by MS(ESI):m / z found[M / 2+1] + =748
[0236] Example 39
[0237] Example 39 (16 mg, yield 17%) was obtained by a similar synthetic route as Example 22, except that compound 22a was replaced by MS(ESI):m / z found[M / 2+1] + =756
[0238] Example 40
[0239] Example 40 (8 mg, 8% yield) was obtained by a similar synthetic route as Example 22, except that compound 22a was replaced by MS(ESI):m / z found[M / 2+1] + =748
[0240] Example 41
[0241] Example 41 (53 mg, yield 22%) was obtained by a similar synthetic route as Example 22, except that compound 22a was replaced by MS(ESI):m / z found[M / 2+1] + =748
[0242] Example 42
[0243] Example 42 (13 mg, 9% yield) was obtained by a similar synthetic route as Example 22, except that compound 22a was replaced by MS(ESI):m / z found[M / 2+1] + =747
[0244] Experimental Example 1: In vitro proliferation inhibition test of tumor cells by the exitecan derivatives of the present invention
[0245] The cell lines used in this experiment were human breast cancer cell line HCC1569, human colorectal adenocarcinoma cell line SW620, human malignant melanoma cell line A375, and human non-small cell lung cancer cell line NCI-H358. 3 Cells were seeded into a 96-well plate at a density of 100 μL / well. 200 μL of PBS was added to the outermost circle to reduce the volatilization of the culture medium. The plate was incubated at 37°C and 5% CO2 for 48 hours. The 96-well plate was then taken out and 100 μL of the diluted compound prepared in the embodiment of the present invention and the positive reference DXD were added to each well. The structural formula of DXD is (Synthesized with reference to patent EP2907824B1). The compounds prepared in the examples of the present invention and the positive reference DXD were diluted to 10 μM in PBS. This was used as the initial concentration, and a five-fold gradient dilution was performed with PBS for a total of nine dilutions, ending at 0 concentration. The plates were incubated at 37°C, 5% CO₂ for 120 hours. The 96-well plates were removed, the culture medium removed, and 100 μL of detection solution (CCK8: culture medium = 1:9) was added to each well. The plates were then incubated at 37°C, 5% CO₂ for 4 hours. The values were read at 450 nm using a microplate reader (TECAN, Cat. No. CEY0017), recorded in Excel, and analyzed using Graphpad Prism 5 software. The experimental results are shown in Tables 1-4.
[0246] Table 1. IC values of the exitecan derivatives of the present invention for inhibition of proliferation of NCI-H358 cells in vitro 50 value
[0247] Conclusion: The exitecan derivatives provided by the present invention have significant proliferation inhibitory activity on NCI-H358 cells, which is better than the positive reference compound DXD.
[0248] Table 2. IC values of the exitecan derivatives of the present invention for inhibition of A-375 cell proliferation in vitro 50 value
[0249] Conclusion: The exitecan derivatives provided by the present invention have significant proliferation inhibitory activity on A-375 cells, which is superior to the positive reference compound DXD.
[0250] Table 3. IC values of the exitecan derivatives of the present invention for inhibition of SW-620 cell proliferation in vitro 50 value
[0251] Conclusion: The exitecan derivatives provided by the present invention have obvious proliferation inhibitory activity on SW-620 cells, which is better than the positive reference compound DXD.
[0252] Table 4. IC values of the exitecan derivatives of the present invention for inhibition of HCC1569 cell proliferation in vitro 50 value
[0253] Conclusion: The exitecan derivatives provided by the present invention have significant proliferation inhibitory activity on HCC1569 cells, which is comparable to that of the positive reference compound DXD.
[0254] Experimental Example 2: Preparation of anti-human HER3 monoclonal antibodies
[0255] The anti-human HER3 monoclonal antibody sequence of the present invention is as follows:
[0256] Complementarity determining region H'CDR1 of the heavy chain variable region of the anti-human HER3 antibody (SEQ ID NO: 1):
[0257] Complementarity determining region H'CDR2 of the heavy chain variable region of the anti-human HER3 antibody (SEQ ID NO: 2):
[0258] Complementarity determining region H'CDR3 of the heavy chain variable region of the anti-human HER3 antibody (SEQ ID NO: 3):
[0259] Complementarity determining region L'CDR1 of the light chain variable region of the anti-human HER3 antibody (SEQ ID NO: 4):
[0260] Complementarity determining region L'CDR2 of the light chain variable region of the anti-human HER3 antibody (SEQ ID NO: 5):
[0261] Complementarity determining region L'CDR3 of the light chain variable region of the anti-human HER3 antibody (SEQ ID NO: 6):
[0262] Anti-HER3 antibody heavy chain variable region (SEQ ID NO: 7):
[0263] Anti-HER3 antibody light chain variable region (SEQ ID NO: 8):
[0264] Anti-HER3 antibody heavy chain: SEQ ID NO: 9
[0265] Anti-HER3 antibody light chain SEQ ID NO: 10
[0266] The anti-human HER3 monoclonal antibody was prepared as follows: the heavy chain and light chain genes synthesized by Nanjing KingSher Biotech Co., Ltd. were constructed into the pCGS3 expression vector. The plasmid was extracted using an endotoxin-free plasmid extraction kit (Tiangen Biochemical Technology Co., Ltd., catalog number: DP117), and the specific operations were carried out according to the instructions. HEK293f cells were cultured using KOP293 cell culture medium (Zhuhai Kairui, catalog number: K03252) at 37°C, 5% CO2 shaker, at a speed of 100-130 rpm, and humidity was controlled at more than 75% for culture. One day before transfection, HEK 293f cells in logarithmic growth phase and in good growth condition were passaged to 2×10 6 / mL, shaker (110rpm, 37℃, 5% CO2) overnight, and transfection was performed the next day. Before transfection, TA-293 (293 cell suspension chemical transfection reagent) and KPM (serum-free cell transfection buffer solution) were preheated at room temperature, and the cell density and viability were measured. The density was 4×10 6 / mL, and the viability must be greater than 98% before use. Transfection was performed according to the instructions for the KOP293 transient transfection protein expression system, and the expression supernatant was harvested by centrifugation 6 days after transfection.
[0267] The expression supernatant was filtered through a 0.45 μM filter and the antibody with the Fc domain was isolated from the expression supernatant using an affinity chromatography column. The equilibration buffer consisted of 9.5 mM sodium dihydrogen phosphate plus 40.5 mM sodium dihydrogen phosphate, pH 7.4; the elution buffer consisted of 0.1 M glycine, pH 3.0. The eluted antibody was replaced with PBS, pH 7.2.
[0268] Experimental Example 3: HER3 ADC Conjugation
[0269] The interchain disulfide bonds were reduced by adding 1 mM EDTA (Invitrogen, Catalog No. AM9260G) and 8-fold molar equivalents of TECP (Thermo, Catalog No. 77720) to a 10 mg / mL HER3 monoclonal antibody solution. The mixture was stirred at 37°C, 250 rpm for 2.5 hours. The mixture was cooled to a target temperature of 4°C and 10 drug equivalents of compounds 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, and 42 were added per mole in the form of a 10% (v / v) DMSO solution (Sigma, Catalog No. D2660). After 3 hours, the antibody drug conjugates were replaced by ultrafiltration using PBS and named HER3-ADC-1, HER3-ADC-2, HER3-ADC-3, HER3-ADC-4, HER3-ADC-5, HER3-ADC-6, HER3-ADC-7, HER3-ADC-8, HER3-ADC-9, HER3-ADC-10, HER3-ADC-11, HER3-ADC-12, HER3-ADC-13, HER3-ADC-14, HER3-ADC-15, HER3-ADC-16, HER3-ADC-17, HER3-ADC-18, HER3-ADC-19, HER3-ADC-21, HER3-ADC-22, HER3-ADC-23, HER3-ADC-24, HER3-ADC-25 HER3-ADC-5, HER3-ADC-6, HER3-ADC-7, HER3-ADC-8, HER3-ADC-9, HER3-ADC-10, HER3-ADC-11, HER3-ADC-12, HER3-ADC-13, HER3-ADC-14, HER3-ADC-15, HER3-ADC-16, HER3-ADC-17, HER3-ADC-18, HER3-ADC-19, HER3-ADC-20, and HER3-ADC-21. The specific structures of the antibody-drug conjugates are shown in Table 5.
[0270] Table 5
[0271] Note: mAb in Table 5 refers to the HER3 monoclonal antibody in the above embodiments and test examples. m is an integer or decimal from 1 to 15 each time it appears, representing the average number of units conjugated to each antibody for each selected drug linker compound. m can also be expressed as DAR.
[0272] After ultrafiltration, the concentration of the ADC conjugated product was determined by absorbance at 280 nm and 365 nm. The successful conjugation was confirmed by HPLC-HIC analysis. Antibody purity was determined by SEC-HPLC. DAR values were determined by LC-MS. The results are shown in Table 6.
[0273] Table 6 ADC drug conjugation results of HER3 antibodies
[0274] The preparation method of the positive reference drug U3-1402 (PATRITUMAB DERUXTECAN) used in the test examples of the present invention was prepared with reference to the preparation method of the antibody-drug conjugate (16a) in patent CN106163559B.
[0275] Experimental Example 4: In vitro proliferation inhibition test of HER3-targeted tumor cells by the antibody-drug conjugate of the present invention
[0276] The cell line used in this experiment was the human non-small cell lung cancer line NCI-H358 with high expression of HER3. 3 Cells were seeded into 96-well plates at a density of 10 cells / 100 μL / well. 200 μL of PBS was added to the outermost circle to reduce evaporation of the culture medium. The plates were incubated at 37°C, 5% CO₂ for 48 hours. The plates were then removed and 100 μL of diluted ADC sample was added to each well. The ADC sample was prepared at 10 μM in PBS. This was used as the starting concentration for a five-fold series of nine dilutions, ending at 0. The plates were incubated at 37°C, 5% CO₂ for 120 hours. The plates were removed, the culture medium removed, and 100 μL of detection solution (CCK8: culture medium = 1:9) was added to each well. The plates were then incubated at 37°C, 5% CO₂ for 4 hours. The readings were read at 450 nm using a microplate reader (TECAN, Cat. No. CEY0017), recorded in Excel, and analyzed using Graphpad Prism 5 software. The results are shown in Table 7.
[0277] Table 7 IC of the HER3-ADC of the present invention on the in vitro proliferation inhibition of NCI-H358 cells 50 value
[0278] Conclusion: The antibody-drug conjugate targeting HER3 of the present invention has significant proliferation inhibitory activity on HER3-positive NCI-H358 cells.
[0279] The present invention has been described through the above-described embodiments. However, it should be understood that the above-described embodiments are for illustrative and illustrative purposes only and are not intended to limit the present invention to the described embodiments. Furthermore, it will be understood by those skilled in the art that the present invention is not limited to the above-described embodiments and that further variations and modifications may be made based on the teachings of the present invention, all of which fall within the scope of the present invention. The scope of protection of the present invention is defined by the appended claims and their equivalents.
Claims
1. A compound having a structure shown in formula A or a pharmaceutically acceptable salt thereof, in, R1 is -C(O)-(CH2) m2 R2; R2 is a 6-10 membered aryl group, a 5-10 membered heteroaryl group containing 1, 2 or 3 heteroatoms independently selected from N, O and S, a 3-8 membered cycloalkyl group or a 3-8 membered heterocycloalkyl group containing 1, 2 or 3 heteroatoms independently selected from N, O and S, and the aryl group, heteroaryl group, cycloalkyl group and heterocycloalkyl group are each independently substituted by 2, 3 or more R3, preferably, the aryl group, heteroaryl group, cycloalkyl group and heterocycloalkyl group are each independently substituted by 2, 3, 4 or 5 R3; R3 is independently selected from halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, amino, nitro, hydroxyl, cyano, C 1-6 Alkoxy, -NH-C 1-6 Alkyl, and -N(C 1-6 alkyl)2, and at least one R3 is an amino group, and when R2 has two R3s, the amino R3 and -C(O)-(CH2) in R1 m2 - the respective attachment sites in R2 are not in a para-positional relationship; and m2 is selected from 1, 2, 3, 4, 5 and 6.
2. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, characterized in that R1 is -CO-CH2-R2; and / or R2 is a 6-10 membered aryl or a 5-10 membered heteroaryl containing 1, 2 or 3 heteroatoms independently selected from N, O and S, and the aryl and heteroaryl are each independently substituted by 2, 3, 4 or 5 R3; preferably, R2 is a 6-10 membered aryl substituted by 2, 3, 4 or 5 R3; preferably, R2 is a phenyl substituted by 2, 3 or 4 R3; and / or Each occurrence of R3 is independently selected from F, Cl, Br, I, C 1-3 Alkyl, C 1-3 Haloalkyl, amino, nitro, hydroxyl, cyano, C 1-3 Alkoxy, -NH-C 1-3 Alkyl, and -N(C 1-3 alkyl)2, and at least one R3 is an amino group, and when R2 has two R3s, the amino R3 and -C(O)-(CH2) in R1 m2 - each of the attachment sites in R2 is not in a para-position relationship; preferably, each occurrence of R3 is independently selected from F, Cl, Br, I, C 1-3 Alkyl, amino, nitro, hydroxyl, cyano and C 1-3 Alkoxy, and at least one R3 is an amino group, and when R2 has two R3s, the amino R3 and -C(O)-(CH2) in R1 m2 - each of the attachment sites in R2 is not in a para-position relationship; preferably, each occurrence of R3 is independently selected from F, Cl, Br, I, C 1-3 Alkyl, and amino, and at least one R3 is amino, when R2 has two R3, the amino R3 and -C(O)-(CH2) in R1 m2 - the respective attachment sites in R2 are not in a para-positional relationship; and / or m2 is 1, 2 or 3; more preferably, m2 is 1.
3. The compound according to claim 1 or 2 or a pharmaceutically acceptable salt thereof, characterized in that: The compound is selected from the following compounds:
4. A compound or a pharmaceutically acceptable salt thereof, wherein the compound has the structure DL, in, D- has the structure of formula I, R A -C(O)-(CH2) m1 R B -NH-; R B is a 6-10 membered arylene group, a 5-10 membered heteroarylene group containing 1, 2 or 3 heteroatoms independently selected from N, O and S, a 3-8 membered cycloalkylene group or a 3-8 membered heterocycloalkylene group containing 1, 2 or 3 heteroatoms independently selected from N, O and S, wherein the arylene group, heteroarylene group, cycloalkylene group and heterocycloalkylene group are each independently substituted by 0, 1, 2 or more R C Preferably, the arylene, heteroarylene, cycloalkylene and heterocycloalkylene are each independently substituted by 0, 1, 2, 3, or 4 R C replace; R C Each occurrence is independently selected from halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, amino, nitro, hydroxyl, cyano, C 1-6 Alkoxy, -NH-C 1-6 Alkyl, and -N(C 1-6 Alkyl)2; m1 is 1, 2, 3, 4, 5, or 6; L has the structure of Formula II: n1 is 1, 2, 3, 4, 5 or 6; n is 0, 1, 2, 3, 4, 5, 6, 7 or 8; n3 is 0, 1, 2, 3, 4, 5, 6, 7 or 8; and L a is a peptide residue consisting of 2 to 7 amino acid residues selected from the group consisting of alanine, phenylalanine, glycine, valine, lysine, citrulline, serine, glutamic acid and aspartic acid residues;.
5. The compound according to claim 4 or a pharmaceutically acceptable salt thereof, characterized in that: R A -CO-CH2-R B -NH-; and / or R B For 0, 1, 2, 3, or 4 R C substituted 6-10 membered arylene or 5-10 membered heteroarylene containing 1, 2 or 3 heteroatoms independently selected from N, O and S; preferably, R B For 0, 1, 2, 3, or 4 R C substituted 6-10 membered arylene; preferably, R B 0, 1, 2, or 3 R C Substituted phenylene; and / or R C Each occurrence is independently selected from F, Cl, Br, I, C 1-3 Alkyl, C 1-3 Haloalkyl, amino, nitro, hydroxyl, cyano, C 1-3 Alkoxy, -NH-C 1-3 Alkyl, and -N(C 1-3 Preferably, R C Each occurrence is independently selected from F, Cl, Br, I, C 1-3 Alkyl, amino, nitro, hydroxyl, cyano and C 1-3 Alkoxy; preferably, R C Each occurrence is independently selected from F, Cl, Br, I, C 1-3 Alkyl, amino and C 1-3 Alkoxy; and / or, m1 is 1, 2 or 3; preferably, m1 is 1; and / or n1 is 1, 2 or 3; preferably, n1 is 1; and / or n is 5, 6 or 7, more preferably n is 6; and / or n3 is 3, 4, 5, 6 or 7, more preferably n3 is 5; and / or L a is a dipeptide residue, a tripeptide residue or a tetrapeptide residue consisting of an amino acid residue selected from alanine, phenylalanine, glycine, valine, lysine, citrulline, serine, glutamic acid, and aspartic acid residues; more preferably L a is a dipeptide residue of a valine residue-alanine residue, a tripeptide residue of an alanine residue-alanine residue-alanine residue, or a tetrapeptide residue of a glycine residue-glycine residue-phenylalanine residue-glycine residue; more preferably L a for 6. The compound according to claim 4 or 5 or a pharmaceutically acceptable salt thereof, characterized in that: L is n is 5, 6 or 7, preferably n is 6.
7. The compound according to any one of claims 4 to 6 or a pharmaceutically acceptable salt thereof, characterized in that: D is selected from the following structures:
8. The compound or pharmaceutically acceptable salt thereof according to any one of claims 4 to 7, characterized in that: The compound is selected from the following structures: Wherein, n is 0, 1, 2, 3, 4, 5, 6, 7 or 8, preferably, n is 5, 6 or 7, and more preferably n is 6.
9. An antibody-drug conjugate as shown in Formula 3, or a pharmaceutically acceptable salt thereof, characterized in that: D as defined in any one of claims 4 to 8; Pc is an antibody or an antigen-binding fragment thereof or a polypeptide; m is an integer or decimal from 1 to 15; L1 has the structure of formula 4: n1 is 1, 2, 3, 4, 5 or 6; n is 0, 1, 2, 3, 4, 5, 6, 7 or 8; n3 is 0, 1, 2, 3, 4, 5, 6, 7 or 8; and L a is a peptide residue consisting of 2 to 7 amino acid residues selected from the group consisting of alanine, phenylalanine, glycine, valine, lysine, citrulline, serine, glutamic acid and aspartic acid residues;.
10. The antibody-drug conjugate according to claim 9, characterized in that: m is an integer or decimal from 1 to 10; preferably, m is an integer or decimal from 3 to 9; more preferably, m is an integer or decimal from 6 to 9; and / or n1 is 1, 2 or 3; more preferably, n1 is 1; and / or n is 5, 6 or 7, more preferably n is 6; and / or n3 is 3, 4, 5, 6 or 7, more preferably n3 is 5; and / or L a is a dipeptide residue, a tripeptide residue or a tetrapeptide residue consisting of an amino acid residue selected from alanine, phenylalanine, glycine, valine, lysine, citrulline, serine, glutamic acid and aspartic acid residues; more preferably L a is a dipeptide residue of a valine residue-alanine residue, a tripeptide residue of an alanine residue-alanine residue-alanine residue, or a tetrapeptide residue of a glycine residue-glycine residue-phenylalanine residue-glycine residue; more preferably L a for Preferably, L1 is Wherein n is 5, 6, or 7, preferably n is 6.
11. The antibody-drug conjugate according to claim 9 or 10, wherein the antibody-drug conjugate is selected from in, n is 0, 1, 2, 3, 4, 5, 6, 7 or 8, preferably, n is 5, 6 or 7, more preferably n is 6; and m is an integer or decimal from 1 to 15; preferably, m is an integer or decimal from 1 to 10; preferably, m is an integer or decimal from 3 to 9; more preferably, m is an integer or decimal from 6 to 9.
12. The antibody-drug conjugate or a pharmaceutically acceptable salt thereof according to any one of claims 9 to 11, wherein the antibody or antigen-binding fragment thereof is selected from a murine antibody, a chimeric antibody, a humanized antibody and a fully human antibody; Preferably, the antibody or antigen-binding fragment thereof is selected from anti-TROP-2 antibody, anti-HER2 (ErbB2) antibody, anti-EGFR antibody, anti-B7-H3 antibody, anti-c-Met antibody, anti-HER3 (ErbB3) antibody, anti-HER4 (ErbB4) antibody, anti-LIV-1 antibody, anti-ROR1 antibody, anti-CD20 antibody, anti-CD22 antibody, anti-CD30 antibody, anti-CD33 antibody, anti-CD44 antibody, anti-CD56 antibody, anti-CD70 antibody, anti-CD73 antibody, anti-CD105 antibody, anti-CEA antibody, anti-A33 antibody, anti-Cripto antibody, anti-EphA2 antibody, anti-G250 antibody, anti-MUCl antibody, anti-LewisY antibody, anti-VEGFR antibody, anti-GPNMB antibody, anti-Integrin antibody, anti-PSMA antibody, anti-Tenascin-C antibody, anti-SLC44A4 antibody and anti-Mesothelin antibody or antigen-binding fragment thereof; Preferably, the antibody or antigen-binding fragment thereof is selected from anti-TROP-2 antibody, anti-HER2 (ErbB2) antibody, anti-HER3 (ErbB3) antibody, anti-LIV-1 antibody and anti-ROR1 antibody or antigen-binding fragment thereof; preferably, the antibody or antigen-binding fragment thereof is anti-HER3 antibody or antigen-binding fragment thereof; preferably, the CDR1 of the heavy chain variable region of the anti-HER3 antibody or antigen-binding fragment thereof is as shown in SEQ ID NO: 1, the CDR2 of the heavy chain variable region is as shown in SEQ ID NO: 2, and the CDR3 of the heavy chain variable region is as shown in SEQ ID NO: 3 The CDR1 of the light chain variable region is shown in SEQ ID NO:4, the CDR2 of the light chain variable region is shown in SEQ ID NO:5, and the CDR3 of the light chain variable region is shown in SEQ ID NO:6; Further preferably, the heavy chain variable region of the antibody or antigen-binding fragment thereof is as shown in SEQ ID NO:7, and the light chain variable region is as shown in SEQ ID NO:8; even further preferably, the heavy chain of the antibody or antigen-binding fragment thereof is as shown in SEQ ID NO:9, and the light chain is as shown in SEQ ID NO:
10.
13. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to any one of claims 1 to 8 or a pharmaceutically acceptable salt thereof, or an antibody drug conjugate according to any one of claims 9 to 12 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, diluent or excipient.
14. Use of the compound or antibody-drug conjugate or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 12, or the pharmaceutical composition according to claim 13, in the preparation of a medicament for treating or preventing a tumor or cancer; preferably, the tumor or cancer is a tumor or cancer associated with HER3 expression; More preferably, the tumor or cancer is breast cancer, colorectal adenocarcinoma, melanoma or lung cancer; further preferably, the cancer associated with HER3 expression is lung cancer.
15. A method for preventing or treating tumors or cancers, comprising administering an effective amount of the compound or antibody-drug conjugate or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 12, or the pharmaceutical composition according to claim 13 to a subject in need thereof; Preferably, the tumor or cancer is a tumor or cancer associated with HER3 expression; More preferably, the tumor or cancer is breast cancer, colorectal adenocarcinoma, melanoma or lung cancer; further preferably, the cancer associated with HER3 expression is lung cancer.
16. The compound or antibody-drug conjugate according to any one of claims 1 to 12 or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition according to claim 13, for use in preventing or treating tumors or cancers; Preferably, the tumor or cancer is a tumor or cancer associated with HER3 expression; Preferably, the tumor or cancer is breast cancer, colorectal adenocarcinoma, melanoma or lung cancer; Preferably, the cancer associated with HER3 expression is lung cancer.
17. The use of the compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 3, characterized in that: The compounds are used as toxins in antibody drug conjugates to prepare antibody drug conjugates.
Citation Information
Patent Citations
Camptothecin derivative and conjugate thereof
CN112125915A
Camptothecin derivative and ligand-drug conjugate thereof
CN114456186A
B7H3 antibody-avitecan analogue conjugate and medical application thereof
CN115605510A
Ligand-drug conjugate of exatecan analogue, preparation method therefor and application thereof
WO2020063676A1
B7h3 antibody-exatecan analogue conjugate and pharmaceutical use thereof
WO2021190586A1
Cited By
Pharmaceutical composition for treatment and / or prevention of cancer
CN123036312A
Pharmaceutical composition for treating and / or preventing cancer
WO2025206085A1
